1. Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report
   Wenhua Liang et al, 2016, BMC Cancer CrossRef
2. When not even four ALK inhibitors are enough
   Martin Svatoň et al, 2020, Onkologie CrossRef
3. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
   Richard Bayliss et al, 2016, Cellular and Molecular Life Sciences CrossRef
4. EML4-ALK-positive lung adenocarcinoma presenting an unusual metastatic pattern in a 29-year-old woman who is alive and well in her third year follow up:A case report
   Fatma Tokat et al, 2017, Respiratory Medicine Case Reports CrossRef
5. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors
   F. Koinis et al, 2018, Clinical and Translational Oncology CrossRef